Two generic drug makers are fighting for access to confidential documents related to amendments by Neurim Pharmaceutical of patents covering its sleep drug Circadin, telling the Federal Court on Thursday privilege had been waived after a phone conversation between the company’s founder and her lawyers from DLA Piper.
ASIC’s newly installed chief on Thursday slammed banks and other financial firms for their “trust deficit” and vowed to deploy “every inch of our powers and tools” to go after violators.
The Australian Competition and Consumer Commission has raised concerns that the proposed $2 billion acquisition of Sydney toll road WestConnex by toll road operator Transurban may stymie competition for toll road projects in Australia.
Optus was ordered Wednesday to temporarily pull an ad that Telstra alleges makes a false and damaging claim about the superiority of Optus’ mobile network.
Construction, Forestry, Mining, and Energy Union bosses John Setka and Shaun Reardon have walked free from court after prosecutors on Wednesday dropped blackmail charges related to the union’s boycott of Boral concrete.
The Federal Court has ordered appliance and furniture leasing company Radio Rentals to pay a $2 million penalty for failing to verify consumers’ financial situations before signing them up for leases.
The Full Federal Court on Tuesday dismissed an appeal by aviation services company Aerocare of a ruling rejecting an enterprise agreement the Transport Workers Union called “substandard”.
The financing arrangement underwriting Quinn Emanuel’s shareholder class action against AMP, which will earn its partner Burford Capital a record low 10 percent of any recovery, sets a new standard in class action litigation funding, and is expected to spark greater price competition in the industry.
Apple has lost its bid to be represented by an outside lawyer in an unfair dismissal dispute, with the Fair Work Commission saying Monday the case was not inherently complex and the company’s inhouse legal counsel had time to bone up employment litigation.
Drug giant F. Hoffman-La Roche asked the Federal Court Tuesday for an order barring the release of a generic version of its blockbuster cancer drug MabThera by a unit of Swiss rival Novartis, which it claims could lead to “tens of millions of dollars” in losses.